<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02357368</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00072549</org_study_id>
    <secondary_id>1R01HD095741-01A1</secondary_id>
    <secondary_id>5K23HD078153-05</secondary_id>
    <nct_id>NCT02357368</nct_id>
  </id_info>
  <brief_title>Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk</brief_title>
  <official_title>Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lisa Haddad</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective cohort study focusing on HIV negative women. The investigators want to
      learn how the contraceptive methods of depot medroxyprogesterone acetate (DMPA), etonogestrel
      impant (Eng-Implant), levonorgestrel intrauterine device (Lng-IUD) and the ParaGard® T 380A
      Intrauterine Copper Contraceptive impact the vaginal immune environment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The three proposed aims will evaluate the effect of four contraceptive methods (depot
      medroxyprogesterone acetate (DMPA), etonogestrel implant (Eng-Implant), levonorgestrel
      intrauterine device (Lng-IUD) and ParaGard® T 380A Intrauterine Copper Contraceptive) on: (1)
      HIV target immune cells within the female genital mucosa; (2) markers of T-cell activation
      and trafficking within the female genital mucosa; and (3) secreted cytokines and chemokines
      within the female genital mucosa.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">October 23, 2019</completion_date>
  <primary_completion_date type="Actual">October 23, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HIV target immune cells--CCR5 expressing macrophages and dendritic cells (DCs) including myeloid DCs and Langerhans cells (LCs)</measure>
    <time_frame>Week 1, Week 17</time_frame>
    <description>For assessment of HIV target cells, samples will be stained with a Live/Dead viability dye and fluorochrome labeled antibodies against CD3, CD4, CD27, CD45RA, CCR5 and CXCR4. Effector memory (CD45RA-/CD27-) CD3+CD4+ cells will be analyzed for surface expression of HIV co-receptors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in total CD4+ T cells</measure>
    <time_frame>Week 1, Week 17</time_frame>
    <description>For assessment of HIV target cells, samples will be stained with a Live/Dead viability dye and fluorochrome labeled antibodies against CD3, CD4, CD27, CD45RA, CCR5 and CXCR4. CCR5 and CXCR4 will be analyzed for surface expression of total CD4+ T cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in concentration levels of cytokines and chemokines--Interleukin 1 family (IL-1) and Interleukin 10 (IP10)</measure>
    <time_frame>Week 1, Week 17</time_frame>
    <description>Using multiplex Luminex® assays combined with a customized multi-analytical panel of 22 human cytokines and chemokines, investigators will quantify concentrations of cytokines and chemokines in plasma and CVL supernatant</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>HIV</condition>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Depot medroxyprogesterone acetate (DMPA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DMPA will be administered every 12 weeks at 150 mg IM at week 3 of study enrollment and repeated at week 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etonogestrel impant (Eng-Implant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A standard Nexplanon rod Implant will be placed at study week 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levonorgestrel intrauterine device (Lng-IUD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A standard Mirena IUD will be placed at study week 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ParaGard® T 380A Intrauterine Copper Contraceptive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A standard ParaGuard IUD will be placed at study week 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depot medroxyprogesterone acetate (DMPA)</intervention_name>
    <description>DMPA will be administered every 12 weeks at the standard dose of 150 mg IM, beginning from week 3 of study enrollment and repeated at week 15.</description>
    <arm_group_label>Depot medroxyprogesterone acetate (DMPA)</arm_group_label>
    <other_name>Depo Provera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Etonogestrel implant (Eng-Implant)</intervention_name>
    <description>A standard nexplanon rod implant will be placed at study week 3 by a trained clinician.</description>
    <arm_group_label>Etonogestrel impant (Eng-Implant)</arm_group_label>
    <other_name>Nexplanon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Levonorgestrel intrauterine device (Lng-IUD)</intervention_name>
    <description>A standard Mirena IUD will be placed at study week 3 by a trained clinician.</description>
    <arm_group_label>Levonorgestrel intrauterine device (Lng-IUD)</arm_group_label>
    <other_name>Mirena</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ParaGard® T 380A Intrauterine Copper Contraceptive</intervention_name>
    <description>A standard ParaGuard IUD will be placed at study week 3 by a trained clinician.</description>
    <arm_group_label>ParaGard® T 380A Intrauterine Copper Contraceptive</arm_group_label>
    <other_name>ParaGuard</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Age 18-45 years

          -  Normal menses (22-35 day intervals) for at least 3 cycles

          -  Intact uterus and cervix

          -  Interested in to DMPA, Eng-Implant or Lng-IUD or ParaGuard

          -  Willing to delay initiation of hormonal contraception for up to 1 month

          -  Willing to use condoms or abstain from sexual intercourse for at least 48 hours before
             each genital tract sampling (condoms will be made available)

          -  Able and willing to provide informed consent, and undergo serial blood and CVL
             sampling

          -  Negative HIV screening

        Exclusion Criteria:

          -  Pregnant within the last 3 months

          -  Breastfeeding

          -  History of loop electrosurgical excision procedure, conization, or cryosurgery within
             the past year

          -  Use of hormonal contraception or IUD in the past 6 months

          -  Known history of medical condition that would interfere with the conduct of the study

          -  Symptomatic vaginal infection or genital ulcer disease at screening

          -  Taking medications that interact with selected contraceptive

          -  Contraindications to selected contraceptive per the CDC medical eligibility criteria
             or judgment of clinician.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Haddad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Health System</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ponce de Leon Center of the Grady Health System</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Clinical Research Network</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 3, 2015</study_first_submitted>
  <study_first_submitted_qc>February 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2015</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Lisa Haddad</investigator_full_name>
    <investigator_title>Asscoiate Professor</investigator_title>
  </responsible_party>
  <keyword>HIV-negative</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Copper</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Etonogestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

